Fundz
Real-time · AI · Cross-signal

Discover the power of real-time signals plus AI

Every funding round, exec hire, M&A move, contract, and sentiment shift on Laigo Bio — with verified, ICP-scored contact reveals (email + mobile) on demand.

Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.

See plansBook a 15-min walkthrough
▶
Watch the 2-minute tour · with sound

Laigo Bio closes €17M seed funding, with €5.5M coming from new co-lead investor Biovance Capital and existing co-lead investor Kurma Partners, to advance its oncology programs.

PRIVATEMar 23, 2026•2 months ago

Amount Raised

€17 Million

Round Type

seed

UtrechtBiotechnology

Investors

Cancer Research HorizonsRom Utrecht RegionOncode Bridge FundEurazeoAngelini VenturesArgobio StudioCurie CapitalKurma PartnersBiovance Capital

Description

Laigo Bio, an Utrecht-based biotech company, closed the second close of its seed financing round, raising a total of €17M. The latest investment includes €4M from new co-lead investor Biovance Capital and €1.5M from Kurma Partners. The funds will accelerate the development of their Surface Removal Targeting Chimeras (SureTACs) oncology programs. Laigo Bio focuses on innovative therapies utilizing its proprietary protein degradation platform.

Company Information

Company

Laigo Bio

Location

Utrecht, Utrecht, Netherlands

About

Laigo Bio is a pioneering biotechnology company focused on developing novel therapies using its proprietary SureTAC™ precision membrane protein degradation platform. The company aims to target key signaling molecules in oncology and autoimmune diseases through its innovative technology. With a strong leadership team and significant funding, Laigo Bio is positioned to advance its pipeline towards clinical development.

Predictive Intelligence
Strategic

ML-powered predictions for Laigo Bio's next move

Learn about Strategic plan

Related People

Suggested for you
2 contacts

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies.

Watching Laigo Bio? See every signal — funding, hires, M&A, contracts, sentiment.

See plans